drugset
drugset / Trial / NCT06386211

Bioavailability Study of Magne-B6 New Formulation

NCT06386211 ↗

Phase 1 Completed 24 enrolled Opella Healthcare Group SAS
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of the study is to assess the relative bioavailability of two Magne-B6 preparations, in fasting conditions.

Timeline

Start
2024-07-03
Primary completion
2024-08-24
Completion
2024-08-24

Drugs

EvaluationDrugModalityDoseRoute
Subject MAGNE-B6 Unknown — Oral

Indications

No indication recorded.